Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Direct lysis of cancer cells" refers to the mechanism by which some anticancer agents destroy tumor cells by rupturing their plasma membrane, leading to immediate cell death. This is often accomplished by oncolytic viruses, certain biologic drugs, or cytolytic antibodies that interact with specific or general cell surface targets, ultimately causing cell lysis. The resulting cell death can release intracellular contents, sometimes stimulating an immune response against the tumor; however, this is not the name of a specific molecule, gene, or receptor, but rather a description of a functional outcome or therapeutic process[3]. The term is **not** a canonical molecular target and should not be treated as such for database curation or structured information. If you are looking for a specific target mediating direct lysis (such as complement proteins, perforin, or a viral receptor), those should be referenced instead[3].
Physical disruption of cell membrane, Lytic destruction of tumor cells, Induction of necrosis or other forms of regulated cell death
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Direct lysis of cancer cells.